mechan
involv
chronic
hepat
c
progress
incomplet
understood
aim
analyz
associ
synthetas
myxoviru
resist
protein
polymorph
sever
liver
diseas
human
immunodefici
viru
hiv
hepat
c
viru
hcv
coinfect
patient
perform
crosssect
studi
patient
underw
liver
biopsi
dna
genotyp
perform
use
goldeng
assay
outcom
variabl
ion
liver
biopsi
signific
fibrosi
f
ii
moder
activ
grade
addit
model
inherit
genet
associ
test
use
likelihood
signific
fibrosi
f
lower
patient
carri
allel
adjust
odd
ratio
aor
p
besid
likelihood
moder
activ
grade
higher
patient
carri
c
allel
aor
p
g
allel
aor
p
lower
patient
carri
allel
aor
p
allel
aor
p
conclus
polymorph
associ
sever
liver
diseas
hivhcvcoinfect
patient
suggest
signific
role
progress
hepat
fibrosi
minor
patient
may
spontan
clear
hepat
c
viru
hcv
acut
phase
infect
correl
rapid
induct
innat
respons
especi
interferonstimul
gene
isg
howev
major
patient
unabl
clear
hcv
develop
chronic
hepat
c
chc
may
caus
irrevers
fibrosi
lead
cirrhosi
hepatocellular
carcinoma
moreov
chc
acceler
human
immunodefici
viru
hiv
hcv
coinfect
patient
result
higher
rate
diseas
progress
hcv
monoinfect
patient
pathogen
mechan
involv
progress
incomplet
understood
known
altern
liver
inflammatori
profil
impair
immun
respons
thought
import
determin
rate
fibrosi
progress
among
other
chronic
hcv
infect
pronounc
effect
gene
express
subset
isg
oligoadenyl
synthetas
oa
famili
myxoviru
resist
protein
mx
protein
gtpase
act
earli
step
viru
life
cycl
prior
genom
replic
trap
viral
compon
prevent
reach
cellular
destin
oa
protein
abl
synthes
oligom
specif
activ
latent
form
rnasel
may
mediat
rna
degrad
contribut
decay
viral
rna
singl
nucleotid
polymorph
snp
oa
gene
chromosom
mx
gene
chromosom
relat
sever
andor
outcom
scientif
report
doi
viral
infect
tickborn
enceph
west
nile
viru
dengu
viru
coronaviru
hepat
b
regard
hcv
infect
polymorph
relat
hcv
clearanc
acut
hcv
infect
interferon
ifn
therapi
higher
sever
liver
diseas
hcvmonoinfect
patient
howev
knowledg
report
relat
oasmx
snp
sever
liver
diseas
hivhcv
coinfect
patient
aim
studi
analyz
associ
polymorph
sever
liver
diseas
hivhcv
coinfect
patient
characterist
studi
popul
tabl
show
epidemiolog
clinic
characterist
hivhcvcoinfect
patient
time
liver
biopsi
regard
liver
biopsi
signific
fibrosi
f
moder
necroinflammatori
activ
alanin
aminotransferas
alt
iul
polymorph
tabl
show
characterist
snp
display
miss
valu
hwe
p
snp
frequenc
hivhcv
coinfect
patient
compar
snp
frequenc
healthi
subject
ib
found
differ
group
aa
p
ag
p
genotyp
associ
polymorph
liver
diseas
tabl
show
relationship
polymorph
sever
liver
diseas
model
addit
inherit
genet
model
best
fit
data
trend
signific
fibrosi
f
lower
patient
carri
allel
p
trend
moder
activ
grade
higher
patient
carri
c
allel
p
g
allel
p
lower
patient
carri
allel
p
allel
p
nearli
signific
c
allel
p
moreov
likelihood
signific
fibrosi
f
liver
biopsi
lower
patient
carri
allel
adjust
odd
ratio
aor
p
besid
likelihood
moder
activ
grade
higher
patient
carri
c
allel
aor
p
g
allel
aor
p
lower
patient
carri
allel
aor
p
allel
aor
p
figur
show
relat
genet
polymorph
serum
alt
found
patient
carri
cc
genotyp
gg
genotyp
higher
valu
serum
alt
percentag
patient
alt
iul
howev
find
signific
associ
multivari
regress
analysi
data
shown
moreov
also
analyz
relat
polymorph
serum
aspart
aminotransferas
ast
find
associ
data
shown
tabl
show
relationship
among
haplotyp
gene
cluster
sever
liver
diseas
likelihood
moder
activ
grade
liver
biopsi
higher
patient
ctg
haplotyp
aor
p
lower
patient
cta
haplotyp
aor
p
moreov
likelihood
moder
activ
grade
liver
biopsi
lower
patient
agcta
haplotyp
aor
p
knowledg
studi
first
descript
relationship
polymorph
sever
liver
diseas
hivhcvcoinfect
patient
major
find
present
studi
c
allel
g
allel
ctg
haplotyp
associ
higher
odd
moder
activ
grade
liver
biopsi
allel
allel
agcta
haplotyp
relat
lower
likelihood
moder
activ
grade
besid
allel
relat
lower
likelihood
signific
fibrosi
f
liver
biopsi
thu
polymorph
might
play
role
develop
liver
diseas
hivhcvcoinfect
patient
studi
includ
control
group
show
studi
cohort
allel
genotyp
frequenc
similar
gener
popul
howev
found
signific
differ
allel
genotyp
frequenc
hivhcv
coinfect
patient
iberian
popul
spain
hapmap
data
observ
might
suggest
could
associ
innat
resist
hcv
infect
howev
studi
design
adequ
draw
conclus
due
number
factor
control
exampl
cohort
may
surviv
bia
patient
year
median
hiv
hcv
infect
addit
patient
select
due
candid
antivir
treatment
hcv
progress
liver
diseas
suspect
set
chc
immun
system
initi
attempt
erad
hcv
besid
probabl
promot
hepatocyt
damag
fibrosi
direct
cellular
toxic
releas
inflammatori
cytokin
innat
immun
respons
virus
produc
type
ifn
alpha
beta
induc
express
protein
although
effect
hcv
well
document
high
level
protein
detect
ifntreat
hcv
patient
sustain
virolog
respons
fact
polymorph
promot
region
relat
gene
express
spontan
viral
clearanc
acut
hcv
infect
higher
hepat
fibrosi
score
hepat
activ
grade
respons
ifn
therapi
hcvmonoinfect
patient
silico
analysi
perform
found
seem
implic
proxim
open
chromatin
region
transcript
factor
bind
site
histon
sometim
percentag
calcul
patient
data
miss
abbrevi
bmi
bodi
mass
index
homa
homeostat
model
assess
hcv
hepat
c
viru
cdc
categori
c
center
diseas
control
prevent
classif
system
clinic
categori
c
includ
condit
list
cdc
surveil
case
definit
aid
pibas
protein
inhibitorbas
therapi
nnrtibas
nonnucleosid
marker
distal
regul
furthermor
seem
also
involv
rna
bind
proteinmedi
posttranscript
regul
well
snp
experiment
express
quantit
trait
loci
eqtl
evid
hand
polymorph
missens
variant
might
affect
protein
structur
seem
influenc
exon
splice
enhanc
motif
might
involv
protein
domain
abolish
way
polymorph
could
decreas
express
get
wors
control
hcv
might
therefor
relat
increas
sustain
inflamm
progress
liver
diseas
oa
protein
play
import
role
innat
immun
respons
genet
variant
oa
gene
known
affect
oa
activ
associ
outcom
viral
infect
polymorph
relat
persist
hcv
infect
progress
hcv
diseas
polymorph
exon
splice
acceptor
site
respons
ifn
therapi
hcv
infect
patient
polymorph
associ
predisposit
chc
studi
polymorph
relat
lower
likelihood
signific
liver
diseas
andor
f
indic
aallel
confer
protect
effect
respect
liver
diseas
progress
polymorph
locat
intron
intron
respect
silico
analysi
snp
seem
involv
rna
bind
proteinmedi
posttranscript
gene
regul
way
polymorph
could
increas
express
improv
control
hcv
might
therefor
relat
decreas
sustain
inflamm
progress
liver
diseas
discuss
presenc
polymorph
may
relat
moder
signific
liver
diseas
associ
observ
might
due
proxim
snp
may
modul
gene
express
direct
effect
polymorph
analyz
studi
one
hand
haplotyp
analysi
show
stronger
associ
liver
diseas
found
polymorph
alon
hand
silico
analysi
show
polymorph
alon
could
influenc
express
protein
involv
howev
would
necessari
demonstr
polymorph
may
modifi
express
gene
impact
snp
fibrosi
progress
chc
pick
gwa
previous
carri
howev
found
rel
strong
associ
snp
sever
liver
diseas
hivhcv
coinfect
patient
could
gwa
usual
power
detect
biggest
effect
besid
note
strong
statist
adjust
pvalu
carri
correct
multipl
test
b
studi
snp
candid
maf
greater
case
individu
effect
easili
detect
size
sampl
small
c
discard
effect
hiv
infect
immun
system
could
show
influenc
polymorph
chc
progress
final
sever
aspect
taken
account
correct
interpret
result
firstli
crosssect
studi
limit
number
patient
could
limit
achiev
statist
signific
valu
besid
crosssect
design
natur
analys
may
confound
factor
secondli
data
collect
retrospect
entail
lack
uniform
thirdli
select
patient
met
set
criteria
start
hcv
treatment
eg
alcohol
abus
high
cell
count
control
hiv
replic
good
treatment
adher
may
introduc
select
bia
fourthli
regard
statist
signific
consider
controversi
adjust
pvalu
multipl
test
clinicalorient
studi
studi
hypothesi
support
theori
previou
report
relat
polymorph
sever
andor
outcom
viral
infect
includ
hcv
infect
therefor
liter
random
search
meaning
result
result
affect
fact
carri
high
number
statist
test
fifthli
studi
perform
patient
european
ancestri
would
interest
perform
analys
differ
ethnic
group
final
studi
includ
hivhcvcoinfect
patient
would
interest
know
role
studi
polymorph
hcv
monoinfect
patient
access
cohort
hcv
monoinfect
patient
conclus
polymorph
associ
sever
liver
diseas
patient
coinfect
hiv
hcv
suggest
polymorph
might
play
signific
role
progress
hepat
fibrosi
analysi
involv
larg
number
patient
need
corrobor
associ
found
studi
popul
perform
crosssect
studi
hivhcvcoinfect
patient
underw
liver
biopsi
septemb
novemb
studi
conduct
accord
declar
helsinki
patient
gave
written
consent
studi
institut
review
board
research
ethic
committe
instituto
de
salud
carlo
iii
approv
studi
particip
patient
sign
inform
consent
form
liver
biopsi
perform
patient
potenti
candid
antihcv
therapi
receiv
previou
ifn
therapi
hcvtreatment
select
criteria
clinic
evid
hepat
decompens
detect
hcv
rna
polymeras
chain
reaction
pcr
neg
hepat
b
surfac
antigen
avail
dna
sampl
lymphocyt
count
higher
l
stabl
combin
antiretrovir
therapi
cart
least
month
studi
entri
need
cart
accord
treatment
revers
transcriptas
inhibitor
base
therapi
tripl
nucleosid
regimen
hiv
human
immunodefici
viru
hivrna
hiv
plasma
viral
load
hcvrna
hcv
plasma
viral
load
alt
alanin
aminotransferas
ast
aspart
aminotransferas
guidelin
use
studi
period
patient
activ
opportunist
infect
activ
drug
addict
concomit
sever
diseas
exclud
subject
includ
studi
european
white
epidemiolog
clinic
data
clinic
epidemiolog
data
obtain
medic
record
durat
hcv
infect
patient
histori
intraven
drug
use
estim
start
first
year
share
needl
inject
paraphernalia
relev
risk
tabl
summari
differ
genotyp
frequenc
relat
sever
liver
diseas
adjust
logist
regress
analysi
polymorph
hivhcv
coinfect
patient
statist
signific
differ
shown
bold
pvalu
calcul
chisquar
test
trend
linear
linear
associ
b
pvalu
calcul
multivari
logist
regress
adjust
import
clinic
epidemiolog
characterist
see
statist
analysi
section
sometim
percentag
calcul
patient
data
miss
abbrevi
ci
confid
interv
aor
adjust
odd
ratio
pvalu
level
signific
moder
activ
metavir
f
signific
fibrosi
metavir
oa
oligoadenyl
synthetas
myxoviru
resist
protein
scientif
report
doi
practic
hcv
transmiss
durat
hcv
infect
calcul
date
initi
hcv
infect
could
determin
certainti
consumpt
g
alcohol
per
day
least
month
consid
high
intak
bodi
mass
index
bmi
calcul
weight
kilogram
divid
squar
height
meter
biochemistri
panel
measur
use
autoanalyz
hitachi
boehring
mannheim
germani
patient
fast
degre
insulin
resist
estim
patient
use
homeostat
model
assess
homa
fast
plasma
glucos
mmoll
time
fast
serum
insulin
mul
divid
hcv
assay
hcv
infect
document
patient
enzymelink
immunosorb
assay
pcr
test
hcv
genotyp
determin
hybrid
biotinlabel
pcr
product
oligonucleotid
probe
bound
nitrocellulos
membran
strip
innolipa
hcv
ii
innogenet
ghent
belgium
plasma
hcvrna
viral
load
measur
pcr
coba
amplicor
hcv
monitor
test
branchburg
nj
usa
realtim
pcr
coba
ampliprepcoba
taqman
hcv
test
result
report
term
intern
unit
per
millilit
iuml
limit
detect
vari
iuml
iuml
depend
hcv
diagnost
test
use
time
biopsi
patient
hcv
viral
load
limit
detect
hcv
rna
level
uiml
chosen
cutoff
low
vs
high
viral
load
circul
hcv
rna
liver
biopsi
liver
biopsi
perform
describ
previous
sampl
alway
evalu
pathologist
unawar
patient
clinic
laboratori
data
liver
fibrosi
necroinflammatori
activ
estim
accord
metavir
score
follow
fibrosi
mild
fibrosi
signific
fibrosi
advanc
fibrosi
definit
cirrhosi
degre
necroinflamm
activ
grade
score
follow
activ
mild
activ
moder
activ
sever
activ
genotyp
dna
polymorph
common
snp
gene
chromosom
gene
chromosom
select
use
databas
hapmap
project
http
snpcshlorg
ncbi
dbsnp
http
wwwncbinlmnihgoventrez
select
criteria
snp
locat
put
regulatori
region
splice
control
element
sce
missens
variant
ii
minor
allel
frequenc
maf
greater
european
peopl
order
guarante
obtain
signific
associ
work
small
sampl
size
set
found
three
snp
gene
intron
intron
exon
missens
five
snp
oa
gene
intron
intron
utr
exon
missens
utr
final
five
polymorph
select
tagsnp
accord
linkag
disequilibrium
ld
fig
two
snp
three
snp
oa
three
snp
discard
analysi
individu
associ
snp
high
linkag
disequilibrium
ld
fig
genom
dna
extract
peripher
blood
qiagen
kit
qiaamp
dna
blood
midimaxi
qiagen
hilden
germani
dna
sampl
sent
spanish
nation
genotyp
center
cegen
http
wwwcegenorg
dna
genotyp
use
goldeng
assay
veracod
technolog
illumina
inc
san
diego
california
usa
moreov
healthi
subject
frequenc
allel
genotyp
studi
polymorph
obtain
use
genom
project
websit
http
provid
broad
represent
common
human
genet
variat
appli
wholegenom
sequenc
divers
set
individu
multipl
popul
select
ib
iberian
popul
spain
popul
includ
individu
outcom
variabl
primari
outcom
variabl
relat
sever
liver
diseas
signific
fibrosi
f
moder
activ
grade
outcom
develop
minimum
followup
time
year
hcv
infect
chisquar
test
chisquar
test
trend
linear
linear
associ
student
ttest
multivari
logist
regress
analysi
use
investig
relationship
among
oa
polymorph
sever
liver
diseas
includ
snp
enter
algorithm
forc
entri
covari
stepwis
algorithm
step
factor
consid
remov
entri
pvalu
entri
exit
respect
thu
logist
regress
test
adjust
signific
covari
associ
one
outcom
variabl
avoid
overfit
regress
covari
use
gender
age
alcohol
intak
biopsi
studi
bmi
homa
nadir
tcell
aid
undetect
hivrna
copiesml
tcell
time
cart
type
cart
hcvrna
iuml
time
hcv
infect
hcv
genotyp
besid
also
use
data
polymorph
polymorph
alreadi
publish
us
show
signific
associ
liver
fibrosi
hivhcv
coinfect
patient
genet
associ
studi
carri
accord
genet
model
best
fit
data
addit
recess
domin
codomin
overdomin
analys
test
accord
good
fit
evalu
akaik
inform
criterion
aic
valu
bayesian
inform
criterion
bic
analys
perform
use
ibm
spss
statist
window
version
ibm
corp
chicago
armonk
ny
usa
hardyweinberg
equilibrium
hwe
snp
assess
chisquar
test
consid
equilibrium
p
addit
pairwis
linkag
disequilibrium
ld
analysi
comput
detect
intermark
relationship
use
standard
r
valu
haploview
softwar
haplotypebas
associ
test
perform
use
plink
softwar
http
pngumghharvardedupurcellplink
compar
haplotyp
rest
haplotyp
refer
categori
pvalu
twotail
statist
signific
defin
p
diagon
repres
differ
snp
squar
repres
pairwis
comparison
two
snp
abbrevi
oa
oligoadenyl
synthetas
myxoviru
resist
protein
